📣 VC round data is live. Check it out!
- Public Comps
- AOTI
AOTI Valuation Multiples
Discover revenue and EBITDA valuation multiples for AOTI and similar public comparables like Creo Medical Group, BioStem Technologies, Cumberland, Pentixapharm Holding and more.
AOTI Overview
About AOTI
AOTI Inc produces, rents, and sells medical devices to help resolve severe acute and chronic wounds for customers globally. The company provides efficacious topical wound oxygen solutions for use in both the institutional and the home care setting to improve the health, well-being, and independence of patients. Its products include TWO2 Extremity Chamber, TWO2 Multi-Patch.
Founded
2008
HQ

Employees
N/A
Website
Financials (FY)
EV
$92M
Valuation Multiples
Start free trialAOTI Financials
AOTI reported last fiscal year revenue of $67M and EBITDA of $8M.
In the same fiscal year, AOTI generated $58M in gross profit, $8M in EBITDA, and $3M in net income.
AOTI P&L
In the most recent fiscal year, AOTI reported revenue of $67M and EBITDA of $8M.
AOTI is profitable as of last fiscal year, with gross margin of 87%, EBITDA margin of 11%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
AOTI Stock Performance
AOTI has current market cap of $84M, and enterprise value of $92M.
Market Cap Evolution
AOTI's stock price is $0.79.
AOTI share price decreased by 34.0% in the last year.
AOTI has an EPS (earnings per share) of $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $92M | $84M | 0.1% | 0.0% | 66.7% | -34.0% | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAOTI Valuation Multiples
AOTI trades at 1.4x EV/Revenue multiple, and 12.2x EV/EBITDA.
AOTI Financial Valuation Multiples
As of June 3, 2026, AOTI has market cap of $84M and EV of $92M.
AOTI has a P/E ratio of 31.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AOTI Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


AOTI Margins & Growth Rates
In the most recent fiscal year, AOTI reported gross margin of 87%, EBITDA margin of 11%, and net margin of 4%.
AOTI Margins
AOTI Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
AOTI Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
AOTI Competitors
AOTI competitors include Creo Medical Group, BioStem Technologies, Cumberland, Pentixapharm Holding, Agfa-Gevaert, Sera Prognostics, Applied BioCode, electroCore, Vuno and FluoGuide.
Most AOTI public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 13.6x | 7.4x | (2.1x) | (4.2x) | |||
| - | 1.5x | - | - | |||
| 1.9x | - | 28.8x | - | |||
| 692.8x | - | (4.1x) | - | |||
| 0.2x | 0.2x | 3.1x | 3.1x | |||
| 431.9x | 157.6x | (1.1x) | (1.0x) | |||
| 4.2x | - | (13.9x) | - | |||
| 2.5x | 2.2x | (9.1x) | (10.5x) | |||
This data is available for Pro users. Sign up to see all AOTI competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AOTI
| When was AOTI founded? | AOTI was founded in 2008. |
| Where is AOTI headquartered? | AOTI is headquartered in United States. |
| Who is the CEO of AOTI? | AOTI's CEO is Michael Stephen Griffiths. |
| Is AOTI publicly listed? | Yes, AOTI is a public company listed on London Stock Exchange. |
| What is the stock symbol of AOTI? | AOTI trades under AOTI ticker. |
| When did AOTI go public? | AOTI went public in 2024. |
| Who are competitors of AOTI? | AOTI main competitors include Creo Medical Group, BioStem Technologies, Cumberland, Pentixapharm Holding, Agfa-Gevaert, Sera Prognostics, Applied BioCode, electroCore, Vuno, FluoGuide. |
| What is the current market cap of AOTI? | AOTI's current market cap is $84M. |
| What is the current revenue of AOTI? | AOTI's last fiscal year revenue is $67M. |
| What is the current EV/Revenue multiple of AOTI? | Current revenue multiple of AOTI is 1.4x. |
| Is AOTI profitable? | No, AOTI is not profitable. |
| How many companies AOTI has acquired to date? | AOTI hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies AOTI has invested to date? | AOTI hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to AOTI
Lists including AOTI
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.